Winkler K, Gaedicke G, Grosch-Wörner I, Marsmann G, Lndbeck G
Klin Padiatr. 1977 Jan;189(8):74-88.
From December 1971 until July 1973 44 children with ALL have been treated according to branch A of the randomised DAL study series of June 3rd 1972 (1/71), which is a slight modification of study VII of Memphis. Afterwards until July 1975 34 patients received a somewhat intensified initial therapy (11/73). The results of 1/71 with a 3-year-remission rate of 39% and an expected 5-year-remission rate of 32% are comparable to those of study VII. The results of 11/73 with an expected 3-year-remission rate of 54% seems clearly superior and unterline the importance of an intensive initial therapy, like it is introduced now in a still more aggressive manner in our running protocol III/75. Therapy mortality was found to be about 5% and seemed to be dependant on the staff's experience. Cytosin-arabinoside orally proved effective as a prophylactic measure during incubation as well as a therapeutic agent in manifest varicalla/zoster infections.
从1971年12月至1973年7月，44名急性淋巴细胞白血病患儿按照1972年6月3日随机DAL研究系列（1/71）的A组方案接受治疗，该方案是对孟菲斯研究VII的轻微修改。此后至1975年7月，34名患者接受了强度稍高的初始治疗（11/73）。1/71方案的3年缓解率为39%，预期5年缓解率为32%，与研究VII的结果相当。11/73方案预期的3年缓解率为54%，似乎明显更优，突出了强化初始治疗的重要性，就像我们现行的III/75方案中以更积极的方式采用的那样。治疗死亡率约为5%，似乎取决于工作人员的经验。口服阿糖胞苷在潜伏期作为预防措施以及在明显的水痘/带状疱疹感染中作为治疗药物均被证明有效。
